⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320422 | 1.00 | — | — | |
| SCHEMBL11211818 | 1.00 | — | — | |
| SCHEMBL6416315 | 1.00 | — | — | |
| SCHEMBL629107 | 1.00 | — | — | |
| SCHEMBL11205919 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL3455926 | 0.88 | — | — | |
| SCHEMBL29894251 | 0.78 | — | — | |
| SCHEMBL41921 | 0.78 | — | — | |
| SCHEMBL6702143 | 0.73 | ALDH1A1 (0.50) | — | |
| SCHEMBL6651106 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0002588-B1 | PLEUROMUTILIN GLYCOSIDE DERIVATIVES, FORMULATIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | ELI LILLY AND COMPANY (US) | 1983-04-06 | — | — | EP | claimed |
| US-20260007762-A1 | ANTI-ROR2 ANTIBODY-DRUG CONJUGATES | SOLVE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-RE50631-E1 | ROR1 antibody immunoconjugates | VelosBio Inc. | 2025-10-14 | — | — | US | disclosed |
| CN-114728078-B | Extracellular vesicles linked to molecules and uses thereof | 隆萨销售股份公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-113423430-B | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-113747925-B | Extracellular vesicle conjugates and uses thereof | 隆萨销售股份公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240189430-A1 | EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY | LONZA SALES AG (CH) | 2024-06-13 | — | — | US | disclosed |
| US-20240108747-A1 | EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF | LONZA SALES AG (CH) | 2024-04-04 | — | — | US | disclosed |
| CN-111587124-B | ROR1 antibody immunoconjugates | 维洛斯生物股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4178559-A1 | NOVEL ROR1 ANTIBODY IMMUNOCONJUGATES | Velosbio Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230022796-A1 | Methods and compositions for modulating the glycosylation profile of proteins | MERCK PATENT GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3057618-B1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX BV (NL) | 2022-12-14 | — | — | EP | disclosed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-4077371-A1 | METHODS AND COMPOSITIONS FOR MODULATING THE GLYCOSYLATION PROFILE OF PROTEINS | Merck Patent GmbH (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114761427-A | Methods and compositions for modulating the glycosylation profile of proteins | 默克专利股份公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220133901-A1 | ROR1 ANTIBODY IMMUNOCONJUGATES | VelosBio Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3991752-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | Hangzhou Dac Biotech Co., Ltd (CN) | 2022-05-04 | — | — | EP | disclosed |